Maliha Sadick

Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnostic measures

ZusammenfassungDie hereditäre hämorrhagische Teleangiektasie (HHT), auch als Morbus Rendu-Osler-Weber bekannt, ist eine autosomal-dominant vererbte Erkrankung des Gefäßbindegewebes. Die Erkrankung wird charakterisiert durch die klassische Trias bestehend aus (muko-)kutanen Teleangiektasien, arteriovenösen Malformationen mit rezidivierender Epistaxis und Hämorrhagien sowie der Heredität. Eine Vielzahl unterschiedlicher klinischer Manifestationsformen der HHT sind beschrieben worden. In mehr als 90% der Fälle stellt die Epistaxis das klinische Erstsymptom dar, wodurch Hals-Nasen-Ohrenärzten eine wichtige Schlüsselrolle in der Diagnosestellung und der Behandlung der HHT zukommt. Trotz neuester diagnostischer und therapeutischer Entwicklungen ist eine Heilung dieser, den Betreffenden in seiner Lebensqualität oft einschränkenden Erkrankung nicht möglich. Außer der Nase sind vor allem die Haut, die Lunge, das Hirn, die Leber und der Gastrointestinaltrakt von arterio-venösen Malformationen (AVM) befallen. Die Entstehung der HHT wird im wesentlichen Mutationen zweier Gene zugeschrieben. Zum einen handelt es sich hierbei um Endoglin (ENG) auf Chromosom 9q33-q34 und activin-receptor like kinase (ALK1) auf Chromosom 12q13. Mutationen von Endoglin werden dem HHT Typ 1 zugeschrieben mit einer Inzidenz von bis zu 40% für pulmonale arteriovenöse Malformationen (AVM). Mutationen von ALK1 entsprechen dem HHT Typ 2 mit einer Inzidenz von bis zu 14% für pulmonale AVM. Diese Arbeit dient zum besseren Verständnis der Komplexität der HHT-Erkrankung, wobei anhand einer Übersicht zur aktuellen Literatur vor allem ein Schwerpunkt auf die klinischen Manifestationsformen, die Molekulargenetik und die Diagnosemöglichkeiten gelegt werden soll. Therapeutische Optionen in der Behandlung der HHT sind hier bewusst nicht erwähnt worden, da sie Gegenstand einer weiteren Arbeit sind. Dadurch, dass die HHT häufiger vorkommt als vermutet und eine weite Bandbreite klinischer Manifestationen aufweisen kann, stellt sie für viele Subspezialisierungen eine enorme Herausforderung dar, die ein eingehendes interdisziplinäres diagnostisches Screening in der Behandlung verlangt.SummaryHereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber disease, is an autosomal dominant disorder of the fibrovascular tissue. It is characterized by the classic triad of (muco-)cutaneous telangiectases, arteriovenous malformations with recurrent epistaxis and hemorrhages, and inheritance. A wide variety of clinical manifestations in HHT have been described. In more than 90% of the patients, nosebleeds are the first predominant symptom, therefore ENT physicians often play a key role as far as diagnosis and management of the disease are concerned. In spite of recent diagnostic and therapeutic progress, a cure for this often burdening and handicapping disease is still not available. Apart from affecting the nose, arteriovenous malformations (AVMs) may also affect the skin, lungs, brain, liver and gastrointestinal tract. The two known genes that are implicated in HHT are endoglin (ENG) located on chromosome 9q33-q34 and activin-receptor-like kinase (ALK1) located on chromosome 12q13. Mutations of ENG are observed in HHT type 1 with an incidence up to 40% for pulmonary AVMs, whereas mutations of ALK1 are observed in HHT type 2 with an incidence of only 14% for pulmonary AVMs, which clinically distinguishes these two types of mutation. The emphasis of this paper is mainly on the clinical manifestation, molecular genetics and diagnosis of HHT, taking account of current literature on HHT in order to better understand the complexity of the disease. Recent therapeutic options in the treatment of HHT have been omitted from this paper as they are subject of a following paper. HHT is more common than previously thought and shows a broad range of different clinical organ manifestations that can be sources of substantial morbidity and mortality, making HHT a continuing challenge for many sub-specialties where interdisciplinary diagnostic screening is mandatory in the management of the disease.

Transcutaneous assessment of renal function in conscious rats with a device for measuring FITC-sinistrin disappearance curves

Determination of the urinary or plasma clearance of exogenous renal markers, such as inulin or iohexol, is considered to be the gold standard for glomerular filtration rate (GFR) measurement. Here, we describe a technique allowing determination of renal function based on transcutaneously measured elimination kinetics of fluorescein isothiocyanate (FITC)-sinistrin, the FITC-labeled active pharmaceutical ingredient of a commercially available marker of GFR. A low cost device transcutaneously excites FITC-sinistrin at 480  nm and detects the emitted light through the skin at 520  nm. A radio-frequency transmission allows remote monitoring and real-time analysis of FITC-sinistrin excretion as a marker of renal function. Due to miniaturization, the whole device fits on the back of freely moving rats, and requires neither blood sampling nor laboratory assays. As proof of principle, comparative measurements of transcutaneous and plasma elimination kinetics of FITC-sinistrin were compared in freely moving healthy rats, rats showing reduced kidney function due to unilateral nephrectomy and PKD/Mhm rats with cystic kidney disease. Results show highly comparable elimination half-lives and GFR values in all animal groups. Bland-Altman analysis of enzymatically compared with transcutaneously measured GFR found a mean difference (bias) of 0.01 and a -0.30 to 0.33 ml/min per 100 g body weight with 95% limit of agreement. Thus, with this device, renal function can be reliably measured in freely moving rats eliminating the need for and influence of anesthesia on renal function.

Transcutaneous measurement of glomerular filtration rate using FITC-sinistrin in rats

BACKGROUND Inulin/sinistrin (I/S) clearance is a gold standard for an accurate assessment of glomerular filtration rate (GFR). Here we describe and validate an approach for a transcutaneous determination of GFR by using fluorescein-isothiocyanate-labelled sinistrin (FITC-S) in rats. METHODS Using a small animal imager, fluorescence is measured over the depilated ear of a rat after the injection of FITC-S. The decay curve of fluorescence is used for the calculation of half-life and GFR. The thus obtained transcutaneous data were validated by simultaneously performed enzymatic and fluorometric measurements in plasma of both FITC-S and sinistrin. RESULTS The results of enzymatic sinistrin determination versus transcutaneous half-life of FITC-S or plasma fluorescence correlated well with each other (R(2) > 0.90). Furthermore, Bland-Altman analyses proved a good degree of agreement of the three methods used. The measurements performed in healthy animals as well as different models of renal failure demonstrate its appropriateness in a wide range of renal function. CONCLUSIONS The transcutaneous method described offers a precise assessment of GFR in small animals. As neither blood and/or urine sampling nor time-consuming lab work is required, GFR can be determined immediately after the clearance procedure is finished. This method, therefore, simplifies and fastens GFR determinations in small lab animals compared to conventional bolus clearance techniques based on blood sampling. A low-cost device for the measurement of transcutaneous fluorescence intensity over time is under construction.

Dual-Energy CT Angiography in Peripheral Arterial Occlusive Disease

We sought to study the accuracy of dual-energy computed tomographic angiography (DE-CTA) for the assessment of symptomatic peripheral arterial occlusive disease of the lower extremity by using the dual-energy bone removal technique compared with a commercially available conventional bone removal tool. Twenty patients underwent selective digital subtraction angiography and DE-CTA of the pelvis and lower extremities. CTA data were postprocessed with two different applications: conventional bone removal and dual-energy bone removal. All data were reconstructed and evaluated as 3D maximum-intensity projections. Time requirements for reconstruction were documented. Sensitivity, specificity, accuracy, and concordance of DE-CTA regarding degree of stenosis and vessel wall calcification were calculated. A total of 359 vascular segments were analyzed. Compared with digital subtraction angiography, sensitivity, specificity, and accuracy, respectively, of CTA was 97.2%, 94.1%, and 94.7% by the dual-energy bone removal technique. The conventional bone removal tool delivered a sensitivity of 77.1%, a specificity of 70.7%, and an accuracy of 72.0%. Best results for both postprocessing methods were achieved in the vascular segments of the upper leg. In severely calcified segments, sensitivity, specificity, and accuracy stayed above 90% by the dual-energy bone removal technique, whereas the conventional bone removal technique showed a substantial decrease of sensitivity, specificity, and accuracy. DE-CTA is a feasible and accurate diagnostic method in the assessment of symptomatic peripheral arterial occlusive disease. Results obtained by DE-CTA are superior to the conventional bone removal technique and less dependent on vessel wall calcifications.

Current oncologic concepts and emerging techniques for imaging of head and neck squamous cell cancer

The incidence of head and neck squamous cell carcinoma (HNSCC) is increasing and currently they account for 5% of all malignancies worldwide. Inspite of ongoing developments in diagnostic imaging and new therapeutic options, HNSCC still represents a multidisciplinary challenge. One of the most important prognostic factors in HNSCC is the presence of lymph node metastases. Patients with confirmed nodal involvement have a considerable reduction of their 5-year overall survival rate. In the era of individually optimised surgery, chemotherapy and intensity modulated radiotherapy, the main role of pre- and posttherapeutic imaging remains cancer detection at an early stage and accurate follow-up. The combined effort of early diagnosis and close patient monitoring after surgery and/or radio-chemotherapy influences disease progression and outcome predicition in patients with HNSCC. This review article focuses on currrent oncologic concepts and emerging tools in imaging of head and neck squamous cell cancer. Besides the diagnostic spectrum of the individual imaging modalities, their limitations are also discussed. One main part of this article is dedicated to PET-CT which combines functional and morphological imaging. Furthermore latest developments in MRI are presented with regard to lymph node staging and response prediction. Last but not least, a clinical contribution in this review explains, which information the head and neck surgeon requires from the multimodality imaging and its impact on operation planning.

First multimodal embolization particles visible on x-ray/computed tomography and magnetic resonance imaging.

Objectives:Embolization therapy is gaining importance in the treatment of malignant lesions, and even more in benign lesions. Current embolization materials are not visible in imaging modalities. However, it is assumed that directly visible embolization material may provide several advantages over current embolization agents, ranging from particle shunt and reflux prevention to improved therapy control and follow-up assessment. X-ray- as well as magnetic resonance imaging (MRI)-visible embolization materials have been demonstrated in experiments. In this study, we present an embolization material with the property of being visible in more than one imaging modality, namely MRI and x-ray/computed tomography (CT). Characterization and testing of the substance in animal models was performed. Materials and Methods:To reduce the chance of adverse reactions and to facilitate clinical approval, materials have been applied that are similar to those that are approved and being used on a routine basis in diagnostic imaging. Therefore, x-ray-visible Iodine was combined with MRI-visible Iron (Fe3O4) in a macroparticle (diameter, 40–200 μm). Its core, consisting of a copolymerized monomer MAOETIB (2-methacryloyloxyethyl [2,3,5-triiodobenzoate]), was coated with ultra-small paramagnetic iron oxide nanoparticles (150 nm). After in vitro testing, including signal to noise measurements in CT and MRI (n = 5), its ability to embolize tissue was tested in an established tumor embolization model in rabbits (n = 6). Digital subtraction angiography (DSA) (Integris, Philips), CT (Definition, Siemens Healthcare Section, Forchheim, Germany), and MRI (3 Tesla Magnetom Tim Trio MRI, Siemens Healthcare Section, Forchheim, Germany) were performed before, during, and after embolization. Imaging signal changes that could be attributed to embolization particles were assessed by visual inspection and rated on an ordinal scale by 3 radiologists, from 1 to 3. Histologic analysis of organs was performed. Results:Particles provided a sufficient image contrast on DSA, CT (signal to noise [SNR], 13 ± 2.5), and MRI (SNR, 35 ± 1) in in vitro scans. Successful embolization of renal tissue was confirmed by catheter angiography, revealing at least partial perfusion stop in all kidneys. Signal changes that were attributed to particles residing within the kidney were found in all cases in all the 3 imaging modalities. Localization distribution of particles corresponded well in all imaging modalities. Dynamic imaging during embolization provided real-time monitoring of the inflow of embolization particles within DSA, CT, and MRI. Histologic visualization of the residing particles as well as associated thrombosis in renal arteries could be performed. Visual assessment of the likelihood of embolization particle presence received full rating scores (153/153) after embolization. Conclusions:Multimodal-visible embolization particles have been developed, characterized, and tested in vivo in an animal model. Their implementation in clinical radiology may provide optimization of embolization procedures with regard to prevention of particle misplacement and direct intraprocedural visualization, at the same time improving follow-up examinations by utilizing the complementary characteristics of CT and MRI. Radiation dose savings can also be considered. All these advantages could contribute to future refinements and improvements in embolization therapy. Additionally, new approaches in embolization research may open up.

Evaluation of breath-hold contrast-enhanced 3D magnetic resonance angiography technique for imaging visceral abdominal arteries and veins.

RATIONALE AND OBJECTIVES To evaluate the diagnostic value of breath-hold contrast-enhanced 3D magnetic resonance angiography (MRA) for assessment of the visceral abdominal arteries and veins in patients with suspected abdominal neoplasms. METHODS Twenty-one patients underwent MR imaging on a 1.5 T unit using a body phased-array coil. MRA was performed with a 3D-FLASH sequence (TR 3.8 ms, TE 1.3 ms, flip angle 25 degrees, acquisition time 20 seconds), 8 to 12 seconds after an intravenous bolus injection of Gd-DTPA. The acquisition delay between the arterial and the portal venous phase was 12 seconds. The image quality and the degree of vascular involvement were evaluated using coronal source images and maximum intensity projection reconstructions. Diagnosis was confirmed by surgery/histology. RESULTS Image quality was optimal in more than 85% of the patients (19/21 arterial phase and 17/21 portal venous phase). MRA correctly predicted vascular status in 20 of 21 patients (95%), with complete concordance between MRA results and surgical findings. In one patient with chronic pancreatitis, MRA demonstrated a false-positive finding that could not be confirmed surgically. CONCLUSIONS. Breath-hold contrast-enhanced 3D-MRA is a valuable technique for assessing visceral abdominal arteries and veins.

Two non-invasive GFR-estimation methods in rat models of polycystic kidney disease: 3.0 Tesla dynamic contrast-enhanced MRI and optical imaging

BACKGROUND The aim of this study was the assessment of kidney morphology and glomerular filtration rate (GFR) in rat models of polycystic kidney disease and a healthy control group of Sprague-Dawley rats (SD rats). The performance of two non-invasive GFR estimation methods-3.0 Tesla magnetic resonance imaging (MRI) and optical imaging were investigated. Data of GFR assessment was compared to surrogate markers of kidney function and renal histology. METHODS Optical imaging of GFR was performed transcutaneously in a small animal imaging system with the fluorescent renal marker fluorescein-isothiocyanate-labelled-sinistrin. Morphologic and dynamic renal imaging was done on a clinical 3.0T MR scanner. Renal perfusion analysis was performed with a two-compartment filtration model. RESULTS The healthy SD rats showed physiological levels of creatinine and urea, indicating normal kidney function. These parameters were elevated in the small animal groups of polycystic kidney disease. For the calculation of perfusion and filtration parameters of kidney function in MRI, a 2D turbo FLASH sequence was performed and allowed to distinguish between normal GFR of healthy rats and reduced GFR of rats with polycystic kidney disease. Also, MRI GFR varied among two different rat strains of polycystic kidney disease, according to their status of renal function impairment. Optical imaging GFR confirmed higher GFR values in healthy rats compared to ill rats but did not show different results among the two rat strains of polycystic kidney disease. For this reason, MRI and optical imaging GFR estimation presented an intra-method bias. CONCLUSIONS Both non-invasive estimation methods of GFR, MRI and optical imaging, can differentiate between healthy rats and animals with limited kidney function. Furthermore, optical imaging, unlike MRI, seems to consider that disease progression with increase of renal polycystic deterioration does not correlate with decrease of GFR in the initial stage of compensatory hyperfiltration.

Morphologic and dynamic renal imaging with assessment of glomerular filtration rate in a pcy-mouse model using a clinical 3.0 Tesla scanner.

Objective:Morphologic and dynamic renal imaging is necessary for characterization of kidney function in renal insufficiency. Assessment of renal perfusion and the glomerular filtration rate (GFR) are essential, as the serum creatinine level and urea are not sensitive at an early stage of kidney damage. Currently available GFR estimation methods are time consuming, expensive, and lead to radiation exposure for the patient. Therefore, the aim was to determine the feasibility of morphologic and contrast-enhanced dynamic magnetic resonance imaging for GFR assessment in pcy (polycystic kidneys and fibrosis) mice, using a clinical 3.0 Tesla scanner. Materials and Methods:Fourteen pcy-mice were anesthetized and an internal jugular vein catheter was implanted to which a dedicated extension tube with a 0.28 mm inner diameter was connected, filled with 1:100 &mgr;L diluted gadobutrol (Gadovist Bayer Schering Pharma, Berlin, Germany). Imaging of the mice was performed with a dedicated 8-element mouse coil (Rapid Biomedical, Rimpar, Germany) plugged into a clinical 32-channel 3.0 Tesla magnetic resonance-scanner (Magnetom Verio, Siemens Medical Solution, Erlangen, Germany). In this study, different morphologic sequences comprising a T1-w 3D volume-interpolated breathhold examination, T2-w 2D half-Fourier acquired turbo spin echo (HASTE), T2-w 2D BLADE-TSE with fat saturation, and a T2-w 3D SPACE were acquired. The dynamic sequence performed for assessment of GFR, was a 2D SR-Turbo FLASH sequence. Image analysis and data assessment was performed by 2 radiologists who were experienced in assessment of human kidney disease. A 3-point scale for visual assessment of renal cystic changes in the pcy-mice was applied. The appearance of cysts, considering a detailed demarcation of the cyst with an enhancing rim and a hypointense core, were assessed as detailed: (1) faint (2) and not to be differentiated, (3) findings in the morphologic sequences. Quantitative parameters of renal function (cortex plasma flow mL/100 mL/min, cortex plasma volume mL/100 mL, and PT sec) were fitted to a 2-compartment model and compared with blood samples of creatinine and urea. Histologic progression of cysts and fibrosis in the pcy-mice was analyzed. Results:The T2-w 3D SPACE and T1-w 3D volume-interpolated breathhold examination sequence post contrast with thinnest slice thickness of 1 to 1.2 mm were well suited for delineation of the kidneys with detailed demarcation of the cysts (image quality score: 1.14 ± 0.37 and 1.2 ± 0.70, respectively). The T2-w 2D BLADE-TSE proved feasible, too (image quality score: 1.28 ± 0.59). The T2-w 2D HASTE sequence with minimally achievable slice thickness of 2 mm was not suitable for morphologic assessment (image quality score: 2.9 ± 0.37). The HASTE sequence suffered from blurring artifacts which further decreased the conspicuity of small cystic changes. The 2D SR-Turbo FLASH sequence showed the renal first pass of the contrast agent and enabled assessment of GFR. The data after time resolved 2D SR-Turbo FLASH perfusion analysis was used for GFR evaluation and demonstrated better GFR values in the young pcy-mice (0.558 mL/min) compared with the older pcy-mice (0.066 mL/min). Conclusion:Application of dedicated coils with a clinical 3.0 Tesla magnetic resonance-scanner have proved feasible for morphologic and dynamic renal imaging with assessment of GFR in pcy-mice.

Application of DC Beads in Hepatocellular Carcinoma: Clinical and Radiological Results of a Drug Delivery Device for Transcatheter Superselective Arterial Embolization

Aim: Application of a drug delivery device for transarterial chem-oembolization (TACE) in patients with hepatocellular carcinoma (HCC). Clinical and radiological treatment assessment. Patients and Methods: 24 patients with liver cirrhosis and uni- or multifocal HCC underwent TACE with doxorubicin beads (DC BeadTM). The underly-ing cause of liver cirrhosis was hepatitis (A: n = 7; B: n = 10) or alco-hol consumption (n = 7). Patients presented with Child Pugh stage A (n = 15) and B (n = 9). The mean intrahepatic tumor size, consid-ering the sum of diameters of all lesions treated, was 3.83 cm (±2.4). Liver function and hematological parameters were docu-mented before and after each TACE. Magnetic resonance imaging (MRI) was performed before and 4 weeks after TACE. The T1-w 3D volume-interpolated breathhold exam (VIBE) sequence was applied for evaluation of the therapy response. Results: 24 patients received a total number of 69 TACE treatments with DC beads (mean dose 160 mg). The elevation of liver function parameters after treat-ment did not affect the patients’ clinical condition. The T1-w VIBE sequence proved very valuable for assessment of the intrahepatic tumor spread. Post-contrast images enabled delineation of the viable HCC lesions, hence facilitating the selective transcatheter ap-proach. The tumor marker a-fetoprotein (AFP), available in 19/24 patients, dropped from 347.5 to 299.5 ng/ml, without being a relia-ble predictor of treatment response. A decrease of tumor size after TACE from 3.83 (±2.40) to 3.01 cm (±2.67; p < 0.0001) was evident on the T1w-VIBE sequences. The mean follow-up period was 30 months. At the time of data analysis, 10 (42%) out of 14 patients were alive. Conclusion: TACE with DC beads in HCC offers a safe and efficient treatment resulting in tumor response within a very short time.